PUBLIC COMPANY
save$FULCFulcrum Therapeutics, Inc.
$FULCCambridge, MA, USupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Open-Label Extension Study to Pioneer Study 6058-SCD-101
- phase1Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
- phase1Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
- phase2Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
- phase3Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
- phase2Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
- phase2Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
- phase3Losmapimod Safety and Efficacy in COVID-19
🐶 Hiring Signal
News
- Slate, Fulcrum to combine in reverse mergerFulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.biopharma_dive · 3d ago
- Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsSlate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…fiercebiotech · 3d ago
- Agios scraps sickle cell drugThe study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.biopharma_dive · 1mo ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that